Mecasermin research: studies, doses and safety
Prescription IGF-1 approved for rare childhood growth failure; low blood sugar is a major risk.
Also called: Increlex, rhIGF-1, Recombinant human IGF-I, Somatomedin C.
IGF-1 and analogues · Recombinant human IGF-1 replacement · Evidence: Approved drug.
At least 106 human research reports were found, including case reports and studies that reuse participants. These are not 106 separate trials.
Key studies
- FDA pooled growth studies: Growth increased in a rare pediatric population; most studies lacked a control group. (source)
- Early European replacement study: Early replacement studies showed growth and glucose effects. (source)
- Laron syndrome over three years: Once-daily native IGF-1 improved growth in a small early cohort. (source)
- Ecuador placebo-controlled growth trial: Controlled evidence supports growth effects in GH receptor deficiency. (source)
- 80 versus 120 mcg/kg: The higher dose did not improve measured growth in this small comparison. (source)
- European long-term growth: Growth gains persisted, but most patients remained very short. (source)
Related to Mecasermin
- IGF-1 LR3: An unapproved growth signal with no human trials found.
- Somatropin: Prescription human growth hormone, with no proven anti-aging benefit.
Sources
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Purple Book Search, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- INCRELEX (mecasermin) current prescribing information, revised October 2025, Eton Pharmaceuticals, Inc. · DailyMed / Eton Pharmaceuticals · 2025
- INCRELEX (mecasermin) injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- INCRELEX (mecasermin) injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2024
- Notice to Compounders: Changes that affect compounding as of March 23, 2020, FDA · 2020
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- AusPAR: Mecasermin, Therapeutic Goods Administration
- Increlex, European Medicines Agency
- Increlex, INN-mecasermin, European Medicines Agency
- Know When to Go to the ER, American College of Emergency Physicians · American College of Emergency Physicians
- Mecasermin (Increlex▼): risk of benign and malignant neoplasia, MHRA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.